Print

Available NIH and FDA approved clinical trial at five centers nationwide for patients who have had a first heart attack within the past 2-3 weeks.

What? Phase II clinical trial evaluating the effects of Late Transplantation of Autologous Bone Marrow after Myocardial Infarction (LateTIME).

Where? Participants receive care at these locations:

  • Cleveland Clinic, Cleveland, Ohio
  • Minneapolis Heart Institute, Minneapolis, Minnesota
  • Texas Heart Institute, Houston, Texas
  • University of Florida, Gainesville, Florida
  • Vanderbilt University, Nashville Tennessee

Why? To evaluate safety and effectiveness of using a patient’s own stem cells (autologous) to stimulate new heart muscle and blood vessel growth in their heart.

How? Under anesthesia, a bone marrow sample is taken from the patient’s hip bone. Adult stem cells, which have been selected from the bone marrow, are injected into the patient’s heart using a special tube placed into one of the vessels of the heart. The patient will be followed to assess how their heart responds.

When? This 6-month study is currently accepting patients.  Patients are required to travel to one of the cities listed above for the procedure and for follow-up evaluation over the next 6 months. 

Who may participate? Patients must meet the following criteria:

  • Must be at least 21 years of age
  • Must have a first heart attack with a stent placed 2-3 weeks before recruitment
  • Must be stable
  • Must have depressed heart function

Who may not participate? Patients may not participate if they meet the following criteria:

  • Dangerous heart rhythm
  • History of anemia, liver disease, or other chronic disease
  • Previous coronary artery bypass
  • Unable to provide informed consent
  • Women of child bearing potential not willing to practice an active form of birth control

For more information:

Dr. Lemuel A. Moyé
University of Texas School of Public Health
RAS Building
1200 Herman Pressler
Houston, Texas, 77030
E-mail:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it